GENOR (06998) announced that following shareholder approval of the special resolution regarding the proposed company name change at an extraordinary general meeting, the Registrar of Companies in the Cayman Islands has issued a certificate of change of the company's name of incorporation. The certificate confirms the company's English name has been changed from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited," while its dual foreign language Chinese name has been changed from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司," both effective from 9:00 AM on December 30, 2025 (Hong Kong Time). The Registrar of Companies in Hong Kong issued a Certificate of Change of Name of Registered Non-Hong Kong Company on January 27, 2026, confirming the registration of the company's new English name "Edding Genor Group Holdings Limited" and Chinese name "亿腾嘉和医药集团有限公司" under Part 16 of the Hong Kong Companies Ordinance (Chapter 622). The Board of Directors hereby announces that, to align with the company's current English and Chinese names and to better reflect the business of the enlarged group following the merger completion and the relationship between the company and its controlling shareholder, the English stock abbreviation for the company's shares traded on the Main Board of The Stock Exchange of Hong Kong Limited will be changed from "GENOR" to "EDDING GENOR." The Chinese stock abbreviation will be changed from "嘉和生物" to "亿腾嘉和," effective from 9:00 AM on February 6, 2026. The company's English and Chinese names remain "Edding Genor Group Holdings Limited" and "亿腾嘉和医药集团有限公司," respectively, and the company's Stock Exchange stock code remains "6998."